Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Multicenter, Double-blind, Parallel-group, Active-control Study of the Efficacy and Safety of Sparsentan for the Treatment of Immunoglobulin A Nephropathy

Trial Profile

A Randomized, Multicenter, Double-blind, Parallel-group, Active-control Study of the Efficacy and Safety of Sparsentan for the Treatment of Immunoglobulin A Nephropathy

Recruiting
Phase of Trial: Phase III

Latest Information Update: 31 Jan 2019

At a glance

  • Drugs Sparsentan (Primary) ; Irbesartan
  • Indications IgA nephropathy
  • Focus Registrational; Therapeutic Use
  • Acronyms PROTECT
  • Sponsors Retrophin
  • Most Recent Events

    • 27 Dec 2018 According to a Retrophin media release, company expects enrollment in this study to complete in the first half of 2021, and top-line data from the 36-week primary endpoint efficacy analysis to become available in the first half of 2022.
    • 27 Dec 2018 Status changed from not yet recruiting to recruiting, according to a Retrophin media release.
    • 27 Dec 2018 According to a Retrophin media release, first patient has been dosed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top